Overview

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

This study will aims to determine the maximum tolerated dose of CGC-11047 when used in individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or cisplatin or 5-flurouracil or sunitinib in one of 7 treatment arms. The dose of CGC-11047 will be escalated until the maximum tolerated dose is established.

Phase:

Phase 1

Details

Lead Sponsor:

Progen Pharmaceuticals

Treatments:

Bevacizumab
Cisplatin
Docetaxel
Erlotinib Hydrochloride
Gemcitabine
Leucovorin
Sunitinib